Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment

(2011) S. Singbrant et al.   BLOOD

A Blueprint for Advancing Genetics-Based Cancer Therapy

(2011) William R. Sellers   CELL

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

(2011) Joan Bladé et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy and the activity of pomalidomide on extramedullary myeloma

(2011) K Detweiler Short et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

(2010) J. Hu et al.   BLOOD

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

(2010) S. Bringhen et al.   BLOOD

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

(2010) Ruben Niesvizky et al.   CANCER

Raising the bar for cancer therapy models

(2010) Giulio Francia et al.   NATURE BIOTECHNOLOGY

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

(2010) Mallika Singh et al.   NATURE BIOTECHNOLOGY

Preclinical development of molecular-targeted agents for cancer

(2010) Alberto Ocana et al.   Nature Reviews Clinical Oncology

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

(2009) D. Chauhan et al.   BLOOD

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

(2009) J-F Rossi et al.   BRITISH JOURNAL OF CANCER

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL